Survodutide peptide API

Product Description

Survodutide (BI 456906) is a novel dual agonist of glucagon (GCG) and GLP-1 receptors. It is a synthetic 29-amino acid peptide engineered from the GLP-1 backbone, designed for once-weekly subcutaneous administration. The dual mechanism combines GLP-1-mediated appetite suppression with GCG-mediated energy expenditure increase, offering synergistic effects on weight reduction and metabolic control.

Key Features:

• Dual GCG/GLP-1 receptor agonist

• Once-weekly administration

• Phase 3 clinical-stage asset

• Promotes appetite suppression and energy expenditure

• Direct liver fat reduction for MASH research

Clinical Data:

• Phase 3 (SYNCHRONIZE-1): Up to 16.6% weight loss at 76 weeks (obesity without diabetes)

• 85.1% of participants achieved ≥5% weight reduction

• Significant liver fat reduction observed

• Specifications:

  
  

  
  

  Parameter	Specification
  Appearance	White to off-white lyophilized powder
  Purity (HPLC)	≥98% (≥99% available)
  CAS No.	2805997-46-8
  Molecular Formula	C₁₈₉H₂₉₂N₄₀O₆₁
  Molecular Weight	~3,990 g/mol
  Storage	-20°C, dry, protected from light
  Shelf Life	24 months
  GMP Compliance	cGMP standards

  Applications:

  Obesity and overweight research

  Type 2 diabetes studies

  Metabolic-associated steatohepatitis (MASH/NASH) research

  Metabolic syndrome studies

  Preclinical and clinical trial supply

  Documentation Available:

  Certificate of Analysis (COA)

  Stability study data (24 months)

  GMP statement

  DMF filing support

• 
  

Packaging & Shipping:

Packaging: Sterile bottle

Storage: -20°C, dry, protected from light

Shipping: Temperature-controlled (blue ice/dry ice)